Köbberling J, Schwinn G, Dirks H
Dtsch Med Wochenschr. 1975 Jul 18;100(29):1540-2.
Oral administration of 1.0 or 2.5 mg bromocriptine (CB 154: 2-brom-alpha-ergocryptine) in nine of twelve patients with active acromegaly resulted in a reduction of growth hormone level by 80-90% over 8-10 hours. During treatment for 2-9 months with daily doses of 4.0 to 10.0 mg bromocriptine, there was a sustained reduction of growth hormone levels in these patients. At the same time soft-tissue swellings and tendency towards sweating decreased. In two patients with diabetes mellitus the blood sugar profile improved and in one of them the insulin dose could be markedly reduced. The rise in growth hormone levels after TRH administration also occurred during bromocriptine treatment. In those patients in whom growth hormone levels failed to react to either acute or chronic administration of bromocriptine no rise followed TRH administration. It is possible that in these patients there is a hypophyseal adenoma without hypothalamic control. On gradually increasing dosage bromocriptine was tolerated without side effects.
给12例活动期肢端肥大症患者中的9例口服1.0或2.5毫克溴隐亭（CB 154：2-溴-α-麦角隐亭），8至10小时内生长激素水平降低了80 - 90%。在每日服用4.0至10.0毫克溴隐亭治疗2至9个月期间，这些患者的生长激素水平持续降低。同时，软组织肿胀和出汗倾向减轻。2例糖尿病患者的血糖情况改善，其中1例患者的胰岛素剂量可显著减少。在溴隐亭治疗期间，给予促甲状腺激素释放激素（TRH）后生长激素水平也会升高。在那些生长激素水平对溴隐亭的急性或慢性给药均无反应的患者中，给予TRH后也不会出现升高。这些患者可能存在不受下丘脑控制的垂体腺瘤。随着剂量逐渐增加，溴隐亭耐受性良好，无副作用。
